New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
09:28 EDTREGNRegeneron reports 85.5% of patients achieve EASI-50 in study of dupilumab
Regeneron disclosed in a regulatory filing that on March 4, at the annual meeting of the American Academy of Allergy, Asthma & Immunology, data from a Phase 2a trial evaluating dupilumab, a human monoclonal antibody, in patients with atopic dermatitis were presented at an oral session by Prof. Diamant Thaci. The data presented in slides show 85.5% of patients showed a reduction of EASI-50 over 12 weeks and EASI-75 reduction was seen in 61.8% of patients over 12 weeks.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
07:35 EDTREGNNewYorkBio to hold a conference
Subscribe for More Information
April 24, 2015
06:43 EDTREGNRegeneron price target raised to $527 from $445 at Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use